Actively Recruiting
Study of the Natural History of Alport Syndrome by Establishment of an International Database
Led by Institut National de la Santé Et de la Recherche Médicale, France · Updated on 2025-09-18
700
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Alport syndrome is a rare inherited condition that affects the kidneys, hearing, and eyes due to mutations in genes for type IV collagen chains in the kidney's filtering membrane. Researchers aim to better understand the natural history of this disease, including how kidney failure progresses, and to identify biomarkers that could predict kidney disease progression earlier than currently possible. The study also explores the impact of Alport syndrome on patients' education, work life, and treatment adherence, with collaboration across European countries and support from the French renal rare disease sector. This observational study involves creating a European database to collect detailed information on Alport syndrome patients. Data gathered includes kidney function measurements like estimated glomerular filtration rate (eGFR), urine analysis for blood and protein levels, hearing loss assessments, and eye examinations for related symptoms. The study also tracks blood pressure, treatment tolerance, and quality of life through questionnaires over multiple years. Participants will be followed through regular assessments at 1, 2, and 3 years to monitor kidney function, urine markers, hearing and eye health, blood pressure, and treatment safety. Researchers will also evaluate compliance with prescribed medications and the disease's overall impact on daily living. The study's goal is to collect comprehensive information to support future therapeutic trials and improve understanding of Alport syndrome progression.
CONDITIONS
Brief Title
Eurbio-Alport (RaDiCo Cohort) (RaDiCo Eurbio-Alport)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of Alport syndrome based on electron microscopic kidney biopsy and/or molecular studies and/or abnormal type IV collagen expression on skin or kidney membranes
- Signed informed consent
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 3 years
Participants are observed over time to collect information about the natural history of Alport Syndrome, including kidney function, urine bio-analysis, hypertension, hearing loss, and ocular symptoms.
Visits at 1 year, 2 years, and 3 years
Trial Site Locations
Total: 1 location
1
RaDiCo Eurbio-Alport
Paris, Île-de-France Region, France, 75012
Actively Recruiting
Research Team
L
Laurence Heidet, PHD
B
Bertrand Knebelmann, PHD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here